The BCR-ABL1 Inhibitors Imatinib and Ponatinib Decrease Plasma Cholesterol and Atherosclerosis, and Nilotinib and Ponatinib Activate Coagulation in a Translational Mouse Model

Author(s):
Pouwer, M.G.; Pieterman, E.J.; Verschuren, L.; Caspers, M.P.M.; Kluft, C.; Garcia, R.A.; Aman, J.; Jukema, J.W. (0000-0002-3246-8359); Princen, H.M.G.
Published
2018
Publication type
Article / Letter to editor
atherosclerosisanimal model cardiovascular diseaselipids and lipoprotein metabolismcoagulation/thrombosischolesterolchronic myeloid leukemiacardiovascular side effects
Date issued
2018-06-12
Language
English
Is part of
Frontiers in Cardiovascular Medicine
hdl
1887/86905
doi
10.3389/fcvm.2018.00055
URL
https://www.frontiersin.org/articles/10.3389/fcvm.2018.00055/full